Panobinostat

An indole and hydroxamic acid derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used as an antineoplastic agent in combination with BORTEZOMIB and DEXAMETHASONE for the treatment of MULTIPLE MYELOMA.

Also Known As:

Farydak; LBH 589; LBH589; NVP-LBH589; NVP LBH589; 2-Propenamide, N-hydroxy-3-(4-(((2-(2-methyl-1H-indol-3-yl)ethyl)amino) methyl)phenyl)-, (2E)-

Networked: 599 relevant articles (79 outcomes, 199 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Atadja, Peter: 38 articles (11/2020 - 02/2005)
2.	Richardson, Paul G: 18 articles (11/2021 - 11/2011)
3.	Johnstone, Ricky W: 15 articles (01/2022 - 07/2008)
4.	Lonial, Sagar: 14 articles (01/2021 - 05/2012)
5.	Fiskus, Warren: 14 articles (01/2020 - 02/2005)
6.	Moreau, Philippe: 11 articles (01/2021 - 07/2013)
7.	Ocker, Matthias: 11 articles (05/2016 - 01/2010)
8.	Bhalla, Kapil N: 10 articles (01/2020 - 04/2009)
9.	Younes, Anas: 10 articles (11/2018 - 09/2010)
10.	San-Miguel, Jesús F: 10 articles (10/2017 - 05/2010)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2015 - "Moreover, some of the mice treated with the panobinostat/ATO combination showed complete tumor responses and remained in remission for over 220 days. " 07/01/2016 - "Continuous treatment of tumor bearing TH-MYCN transgenic mice with panobinostat for nine weeks led to a significant improvement in survival as compared with mice treated with panobinostat for a three-week period. " 03/01/2012 - "In line with its in vitro activity, LBH589 achieved a significant reduction in tumor growth in BxPC-3 pancreatic tumor cell line subcutaneous xenograft mouse model. " 01/01/2022 - "According to the L1000CDS2 database, potential targeting drugs were found to reverse the expressions of DEGs, with panobinostat (S1030) validated effective for tumor repression in MTC by in vitro experiments. " 01/01/2021 - "It is expected that panobinostat would be effective in CNS tumors where the IC-50 is in the low nanomolar range. "
2.	Multiple Myeloma 01/01/2010 - "LBH589 may be very effective in multiple myeloma after a multitude of preceding treatments that could not induce a long-term anti-myeloma effect. " 12/01/2018 - "The combination of VRd with panobinostat 10 mg is safe and effective in patients who are newly diagnosed with multiple myeloma and who are transplant eligible. " 01/01/2020 - "Efficacy of Panobinostat for the Treatment of Multiple Myeloma." 01/01/2021 - "Phase II trial of single-agent panobinostat consolidation improves responses after sub-optimal transplant outcomes in multiple myeloma." 10/01/2019 - "The aim of the current study was to elucidate the mechanisms underlying multiple myeloma (MM) resistance to panobinostat monotherapy and to define strategies to overcome it. "
3.	Glioma (Gliomas) 01/01/2019 - "We evaluated the therapeutic efficacy of panobinostat in enhancing the sensitivity of hAT-MSC.sTRAIL-mediated apoptosis in malignant glioma. " 05/01/2016 - "A phase II trial is warranted to assess the efficacy of panobinostat plus FSRT for recurrent glioma. " 03/01/2022 - "4 patients with H3 K27M-mutant glioma were treated with panobinostat as compassionate use. " 03/01/2022 - "Panobinostat in adults with H3 K27M-mutant diffuse midline glioma: a single-center experience." 09/01/2021 - "Glioma cell cultures bearing IDH1mut were significantly more sensitive to the cytotoxic and antiproliferative effects of panobinostat, compared to IDH1wt glioma cells. "
4.	Glioblastoma (Glioblastoma Multiforme) 10/01/2020 - "Finally, we tested whether the combination treatment of gamitrinib and panobinostat exerted therapeutic efficacy in PDX models of glioblastoma (GBM) in mice. " 01/01/2021 - "The present study combined APR‑246 with DZ‑Nep, panobinostat and teomozolomide in order to explore the possibility of restoring p53 function in mutated cases of glioblastoma. " 12/01/2017 - "LBH589 Inhibits Glioblastoma Growth and Angiogenesis Through Suppression of HIF-1α Expression." 01/01/2020 - "The synergistic effect of DZ‑NEP, panobinostat and temozolomide reduces clonogenicity and induces apoptosis in glioblastoma cells." 01/01/2017 - "We compared the survival of the bioluminescent syngenic F98/Fischer344 rat glioblastoma model treated by acute CED of panobinostat-loaded nano-micelles with that of untreated and vehicle-only-treated controls. "
5.	Leukemia 01/01/2022 - "Depletion of pDCs abrogated panobinostat-mediated induction of type I IFN signaling in leukemia cells and impaired therapeutic efficacy, whereas combined treatment with panobinostat and IFNα improved outcomes in preclinical models. " 09/01/2020 - "For children with leukemia, panobinostat was given once daily three days a week each week at 24, 30 and 34 mg/m2/day. " 01/01/2015 - "These findings indicate that overexpression of APP is involved in promoting proliferation and migration of AML1/ETO-positive leukemia cells and can be inhibited by panobinostat, which provide an attractive prospect for treatment of AML1/ETO-positive AML. " 08/01/2013 - "In patients with leukemia and myeloid disorders, 60 mg was the MTD for weekly as well as biweekly panobinostat. " 02/01/2014 - "The combination of MYB knockdown and LBH589 prolonged survival compared to either treatment alone, suggesting that further development of such combinations might lead to effective and safe leukemia therapies."

Related Drugs and Biologics

1.	Histone Deacetylase Inhibitors
2.	Panobinostat
3.	Bortezomib (Velcade)
4.	Histone Deacetylases (Histone Deacetylase)
5.	Sorafenib (BAY 43-9006)
6.	Dexamethasone (Maxidex)
7.	Vorinostat
8.	belinostat
9.	carfilzomib
10.	Valproic Acid (Depakote)

Related Therapies and Procedures

1.	Therapeutics
2.	Drug Therapy (Chemotherapy)
3.	Castration
4.	Radiotherapy
5.	Re-Irradiation